香港股市 將在 4 小時 11 分鐘 開市

Impel NeuroPharma, Inc. (IMPL)

NasdaqGM - NasdaqGM 即時價格。貨幣為 USD。
加入追蹤清單
10.08+0.14 (+1.41%)
收市價: 04:00PM EDT
9.88 -0.20 (-1.98%)
收市後: 04:24PM EDT
全螢幕
交易股價資料並非來自所有市場
前收市價9.94
開市9.83
買盤9.75 x 1000
賣出價10.40 x 1800
今日波幅9.77 - 10.15
52 週波幅6.90 - 34.75
成交量195,876
平均成交量710,578
市值196.657M
Beta 值 (5 年,每月)
市盈率 (最近 12 個月)
每股盈利 (最近 12 個月)-12.37
業績公佈日2021年8月16日
遠期股息及收益率無 (無)
除息日
1 年預測目標價48.00
  • Benzinga

    Impel NeuroPharma To Raise $45M Via Equity Offering

    Impel NeuroPharma Inc's (NASDAQ: IMPL) has priced its previously announced underwritten public offering of 3 million shares at .00 per share for gross proceeds of $45 million. The offer price represents a steep discount of 29% from the last close price of $21.13 on Thursday. The company's stock gained 27.25% to close higher on Thursday at $21.13. See the offer prospectus here. Underwriters have an option to purchase 0.45 million shares. The offering will close by September 14. Impel will use the

  • Benzinga

    48 Biggest Movers From Yesterday

    Gainers Rocket Lab USA, Inc. (NASDAQ: RKLB) jumped 37.3% to settle at $20.72. Rocket Lab reported 1H sales of $29.5 million and announced it has been awarded a contract to deploy an entire satellite constellation for Kinéis. Canaccord Genuity initiated coverage on Rocket Lab USA with a Buy rating and announced a price target of $30. Gevo, Inc. (NASDAQ: GEVO) shares jumped 37.1% to close at $7.94 on Thursday. The company announced with Chevron that the two companies plan to invest in building and

  • Benzinga

    FDA Gives Nod To Nasal Spray Migraine Treatment From Impel NeuroPharma; Stock Jumps

    The FDA has approved Impel NeuroPharma Inc's (NASDAQ: IMPL) Trudhesa (dihydroergotamine mesylate) nasal spray for the acute treatment of migraine with or without aura in adults. Using Impel's Precision Olfactory Delivery technology, Trudhesa gently delivers dihydroergotamine mesylate to the bloodstream through the vascular-rich upper nasal space. The commercial launch of Trudhesa is planned for early October 2021. In the STOP 301 study, 38% had pain freedom, 66% had pain relief, and 52% had free